ArticleWorld journal of surgical oncology2025
A time-dependent model for quantifying postoperative inflammatory trajectories and predicting survival in early triple-negative breast cancer.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Routine Laboratory Biomarkers for Survival Prediction After Limb-Salvage Surgery in Osteosarcoma: Development of a LASSO-Cox Prognostic Model and Internal Validation.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTriple-Negative Breast Cancer (TNBC) is characterized by high heterogeneity and therapeutic limitations, creating an urgent need for quantifiable and readily accessible prognostic markers to optimize risk stratification. Although the baseline values of inflammatory indices are associated with prognosis, the dynamic remodeling process of the immune-inflammatory response after surgery has not been sufficiently explored. This study innovatively introduces the linear slope to quantify the annual rate of change in postoperative inflammatory indices, aiming to construct a prognostic model that integrates dynamic trends.
methodsThis retrospective study included 296 patients with TNBC who underwent adjuvant chemotherapy following surgery. The primary endpoints of the study were disease-free survival (DFS) and breast cancer-specific survival (BCSS). Inflammatory values were log2-transformed, multicollinearity was assessed using the variance inflation factor (VIF), and multivariable Cox proportional hazards regression models were utilized to assess disease-free survival and breast cancer-specific survival. These were integrated with time-dependent receiver operating characteristic (ROC) curves, bootstrap internal evaluation, and SHAP (SHapley Additive exPlanations) for interpreting the predictive model.
resultThe conventional Cox model demonstrated that T stage, N stage, histological grade, lymphovascular invasion(LVI), and perineural invasion(PNI) were independent prognostic factors for both DFS and BCSS (p < 0.05). The time-dependent model revealed that the dynamic changes in log2(SIRI) held significant prognostic value, which was reflected in the contribution value of SIRI in the SHAP. Time-dependent ROC curves showed that the model's predictive performance at 5 and 6 years was superior to that of the traditional model, although the calibration curve suggested the presence of overestimation. The decision curve analysis curve supported its clinical utility within the common threshold range of 0.1-0.3.
conclusionThe time-dependent model effectively quantified the dynamic evolution of postoperative inflammation. The prognostic model integrating it with tumor staging significantly improved the accuracy of prognosis prediction in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.